Answers are grounded in this paper and cite their sources.
Background: Effective anticoagulant approaches in extracorporeal circuits with little impact on hemostasis are still an unmet medical need. Targeted inhibition of activated factor (F)XI might represent an attractive alternative or addition to conventional anticoagulation. Objectives: We aimed to evaluate the additional antithrombotic effect of the monoclonal anti-FXIa antibody osocimab in in vitro and in vivo models of extracorporeal circulation. Methods: ECMO perfusion studies in baboons using unfractionated heparin and osocimab. Results: = 12) in LVAD circuits. Furthermore, it preserved fibrinogen concentrations (HD: 227 mg/dL vs 170 mg/dL; LVADs: 229 mg/dL vs 50 mg/dL; ECMO: 221 mg/dL vs 170 mg/dL) and platelet aggregation and prolonged clotting times in thromboelastometry. In baboons, osocimab significantly reduced the oxygenator's platelet deposition and terminal fibrin content. Conclusion: Osocimab effectively inhibited clotting due to extracorporeal circulation.
No takes yet. Share an insight, caveat, or question.
Samaha et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: